We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio The FDA granted orphan drug designation ...
A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study.
CHICAGO, Nov. 14, 2017 /PRNewswire/ -- Monopar Therapeutics, Inc., an emerging biopharmaceutical company focused on developing innovative drug candidates to improve clinical outcomes in cancer ...
Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and ...
A phase 2 trial is showing that GPX-150 is promising for patients with soft tissue sarcoma. For patients with metastatic nonresectable soft tissue sarcoma (STS), the investigational compound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results